Observational UK records link semaglutide to 40% fewer asthma attacks, 20% fewer COPD exacerbations

Researchers at Imperial College London examined four parallel cohorts totaling 80,000–88,000 adults who started GLP-1 receptor agonists or sulfonylureas. Propensity-matched comparisons used primary-care records to track acute respiratory events over follow-up. Semaglutide showed the largest effect size, consistent with prior signals of anti-inflammatory action via GLP-1 pathways. The absolute reductions were modest yet clinically relevant given high baseline event rates in obese airway-disease populations. Effect modification was strongest in asthma, weaker though still present in COPD. No randomized respiratory endpoints exist yet, so residual confounding by indication or unmeasured lifestyle changes cannot be excluded. Metabolic dysfunction amplifies airway inflammation; weight loss and direct pulmonary effects may both contribute. Current data therefore support testing semaglutide in dedicated respiratory trials rather than immediate label expansion. Planned next steps include incorporation of exacerbation counts, spirometry, and quality-of-life measures into ongoing or new phase 3 metabolic studies, with results expected within three years.